dyslipidemia-pipeline review, h2 2017

dyslipidemia-pipeline review, h2 2017


  • Products Id :- GMDHC9649IDB
  • |
  • Pages: 291
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dyslipidemia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia-Pipeline Review, H2 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 22, 18, 13, 4, 46 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 5 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).

-The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 6

Dyslipidemia-Overview 7

Dyslipidemia-Therapeutics Development 8

Dyslipidemia-Therapeutics Assessment 23

Dyslipidemia-Companies Involved in Therapeutics Development 35

Dyslipidemia-Drug Profiles 65

Dyslipidemia-Dormant Projects 252

Dyslipidemia-Discontinued Products 261

Dyslipidemia-Product Development Milestones 265

Appendix 277

List of Figures

Number of Products under Development for Dyslipidemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Dyslipidemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dyslipidemia-Pipeline by Acasti Pharma Inc, H2 2017

Dyslipidemia-Pipeline by Akcea Therapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Alnylam Pharmaceuticals Inc, H2 2017

Dyslipidemia-Pipeline by Amgen Inc, H2 2017

Dyslipidemia-Pipeline by AstraZeneca Plc, H2 2017

Dyslipidemia-Pipeline by BASF SE, H2 2017

Dyslipidemia-Pipeline by BCWorld Pharm Co Ltd, H2 2017

Dyslipidemia-Pipeline by Bioleaders Corp, H2 2017

Dyslipidemia-Pipeline by BioRestorative Therapies Inc, H2 2017

Dyslipidemia-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Cadila Healthcare Ltd, H2 2017

Dyslipidemia-Pipeline by Cadila Pharmaceuticals Ltd, H2 2017

Dyslipidemia-Pipeline by Cardax Inc, H2 2017

Dyslipidemia-Pipeline by Catabasis Pharmaceuticals Inc, H2 2017

Dyslipidemia-Pipeline by Celon Pharma SA, H2 2017

Dyslipidemia-Pipeline by Cerenis Therapeutics Holding SA, H2 2017

Dyslipidemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Dyslipidemia-Pipeline by CJ HealthCare Corp, H2 2017

Dyslipidemia-Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017

Dyslipidemia-Pipeline by CymaBay Therapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Daewon Pharm Co Ltd, H2 2017

Dyslipidemia-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Dyslipidemia-Pipeline by Eli Lilly and Company, H2 2017

Dyslipidemia-Pipeline by Esperion Therapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Gemphire Therapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Gilead Sciences Inc, H2 2017

Dyslipidemia-Pipeline by GlaxoSmithKline Plc, H2 2017

Dyslipidemia-Pipeline by Golden Biotechnology Corp, H2 2017

Dyslipidemia-Pipeline by HanAll Biopharma Co Ltd, H2 2017

Dyslipidemia-Pipeline by Handok Inc, H2 2017

Dyslipidemia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Dyslipidemia-Pipeline by Huons Global Co Ltd, H2 2017

Dyslipidemia-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Innovent Biologics Inc, H2 2017

Dyslipidemia-Pipeline by InStar Technologies AS, H2 2017

Dyslipidemia-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by JW Pharmaceutical Corp, H2 2017

Dyslipidemia-Pipeline by Kotobuki Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Kowa Company Ltd, H2 2017

Dyslipidemia-Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Lipicard Technologies Ltd, H2 2017

Dyslipidemia-Pipeline by Lipigon Pharmaceuticals AB, H2 2017

Dyslipidemia-Pipeline by LipimetiX Development Inc, H2 2017

Dyslipidemia-Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Dyslipidemia-Pipeline by Nippon Chemiphar Co Ltd, H2 2017

Dyslipidemia-Pipeline by Omeros Corp, H2 2017

Dyslipidemia-Pipeline by Pfizer Inc, H2 2017

Dyslipidemia-Pipeline by Pharmena SA, H2 2017

Dyslipidemia-Pipeline by Protalix BioTherapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Dyslipidemia-Pipeline by Samjin Pharm Co Ltd, H2 2017

Dyslipidemia-Pipeline by Sancilio & Company Inc, H2 2017

Dyslipidemia-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Dyslipidemia-Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Dyslipidemia-Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Dyslipidemia-Pipeline by Viking Therapeutics Inc, H2 2017

Dyslipidemia-Pipeline by Yuhan Corp, H2 2017

Dyslipidemia-Dormant Projects, H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..1), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..2), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..3), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..4), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..5), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..6), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..7), H2 2017

Dyslipidemia-Dormant Projects, H2 2017 (Contd..8), H2 2017

Dyslipidemia-Discontinued Products, H2 2017

Dyslipidemia-Discontinued Products, H2 2017 (Contd..1), H2 2017

Dyslipidemia-Discontinued Products, H2 2017 (Contd..2), H2 2017

Dyslipidemia-Discontinued Products, H2 2017 (Contd..3), H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acasti Pharma Inc

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

AstraZeneca Plc

BASF SE

BCWorld Pharm Co Ltd

Bioleaders Corp

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Cardax Inc

Catabasis Pharmaceuticals Inc

Celon Pharma SA

Cerenis Therapeutics Holding SA

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Connexios Life Sciences Pvt Ltd

CymaBay Therapeutics Inc

Daewon Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

Eli Lilly and Company

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

HanAll Biopharma Co Ltd

Handok Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Hyundai Pharmaceutical Co Ltd

Innovent Biologics Inc

InStar Technologies AS

Jeil Pharmaceutical Co Ltd

JW Pharmaceutical Corp

Kotobuki Pharmaceutical Co Ltd

Kowa Company Ltd

Kuhnil Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipicard Technologies Ltd

Lipigon Pharmaceuticals AB

LipimetiX Development Inc

Lotus Pharmaceutical Co Ltd

Nippon Chemiphar Co Ltd

Omeros Corp

Pfizer Inc

Pharmena SA

Protalix BioTherapeutics Inc

Regeneron Pharmaceuticals Inc

Samjin Pharm Co Ltd

Sancilio & Company Inc

Takeda Pharmaceutical Company Ltd

Tasly Pharmaceutical Group Co Ltd

Torrent Pharmaceuticals Ltd

Viking Therapeutics Inc

Yuhan Corp

select a license
Single User License
USD 2000 INR 142380
Site License
USD 4000 INR 284760
Corporate User License
USD 6000 INR 427140

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com